GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lionco Pharmaceutical Group Co Ltd (SHSE:603669) » Definitions » EV-to-EBITDA

Lionco Pharmaceutical Group Co (SHSE:603669) EV-to-EBITDA : -43.56 (As of Jul. 13, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Lionco Pharmaceutical Group Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lionco Pharmaceutical Group Co's enterprise value is ¥4,268.5 Mil. Lionco Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-98.0 Mil. Therefore, Lionco Pharmaceutical Group Co's EV-to-EBITDA for today is -43.56.

The historical rank and industry rank for Lionco Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:

SHSE:603669' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.32   Med: 22.79   Max: 97.34
Current: -43.56

During the past 13 years, the highest EV-to-EBITDA of Lionco Pharmaceutical Group Co was 97.34. The lowest was -58.32. And the median was 22.79.

SHSE:603669's EV-to-EBITDA is ranked worse than
100% of 724 companies
in the Drug Manufacturers industry
Industry Median: 14.25 vs SHSE:603669: -43.56

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-13), Lionco Pharmaceutical Group Co's stock price is ¥6.02. Lionco Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-0.190. Therefore, Lionco Pharmaceutical Group Co's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Lionco Pharmaceutical Group Co EV-to-EBITDA Historical Data

The historical data trend for Lionco Pharmaceutical Group Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lionco Pharmaceutical Group Co EV-to-EBITDA Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.12 51.04 -27.57 -37.85 -58.83

Lionco Pharmaceutical Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.31 -27.53 -35.82 -58.83 -31.85

Competitive Comparison of Lionco Pharmaceutical Group Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lionco Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lionco Pharmaceutical Group Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lionco Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lionco Pharmaceutical Group Co's EV-to-EBITDA falls into.


;
;

Lionco Pharmaceutical Group Co EV-to-EBITDA Calculation

Lionco Pharmaceutical Group Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4268.454/-97.999
=-43.56

Lionco Pharmaceutical Group Co's current Enterprise Value is ¥4,268.5 Mil.
Lionco Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-98.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lionco Pharmaceutical Group Co  (SHSE:603669) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Lionco Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.02/-0.190
=At Loss

Lionco Pharmaceutical Group Co's share price for today is ¥6.02.
Lionco Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.190.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Lionco Pharmaceutical Group Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lionco Pharmaceutical Group Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lionco Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
Executives
Zhang Jun Ke Director
Wang Wen Nan Director
Tao Xiao Gang Director
Tao Ling Gang Director
Tao Ling Ping Director

Lionco Pharmaceutical Group Co Headlines

No Headlines